Product image of Mycofenolaat Mofetil Accord (Mycophenolate Mofetil) supplied by GNH India

Mycofenolaat Mofetil Accord

Active Ingredient:
Mycophenolate Mofetil
Origin:
EU

Mycofenolaat Mofetil Accord (Mycophenolate Mofetil)

Mycophenolate Mofetil, the active ingredient in Mycofenolaat Mofetil Accord, is an antimetabolite immunosuppressant presented as an oral tablet for oral use. It is employed to prevent organ transplant rejection and to treat lupus nephritis in adult patients.

GNH India supplies Mycofenolaat Mofetil Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and pharmacies worldwide, with distribution across EU and other regulated markets. The company ensures quality compliance with EU pharmacopeial standards.

Manufacturer / TM Owner

Accord Healthcare B.V.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Mycophenolate Mofetil is used in immunosuppressive therapy for conditions involving the immune system.

  • Organ transplant rejection: reduces the risk of acute rejection and supports graft survival.
  • Lupus nephritis: improves renal function and slows disease progression.
  • Solid organ transplantation: helps maintain long‑term graft function across kidney, liver and heart transplants.

How It Works

  • Mycophenolate Mofetil selectively inhibits inosine monophosphate dehydrogenase (IMPDH), the key enzyme for de novo guanosine nucleotide synthesis in lymphocytes. This inhibition lowers intracellular guanosine pools, suppressing proliferation of T‑ and B‑lymphocytes and thereby dampening the immune response that drives graft rejection and autoimmune renal injury.

Side Effects

Mycophenolate Mofetil may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

  • Nausea: mild to moderate gastrointestinal upset.
  • Diarrhea: loose stools often occurring early in therapy.
  • Headache: transient cranial discomfort.
  • Tremor: fine shaking of the hands.
  • Abdominal pain: cramp‑like discomfort.
  • Fatigue: general feeling of tiredness.

Serious or Rare Side Effects

  • Opportunistic infections: increased susceptibility to viral, fungal or bacterial pathogens.
  • Bone‑marrow suppression: leukopenia, anemia or thrombocytopenia.
  • Hepatic toxicity: elevated liver enzymes or hepatitis.
  • Malignancy: heightened risk of post‑transplant lymphoproliferative disorder.
  • Severe allergic reactions: rash, angioedema or anaphylaxis.

Precautions & Warnings

Before initiating therapy, clinicians should consider several safety measures.

  • Monitor blood counts: perform regular complete blood count assessments.
  • Assess renal function: evaluate serum creatinine and glomerular filtration rate.
  • Pregnancy risk: avoid use in pregnancy; advise effective contraception.
  • Hepatic impairment: adjust dose or monitor liver enzymes closely.
  • Live vaccines: contraindicated due to immunosuppression.
  • Store at ambient temperature: keep below 25 °C in the original packaging, protect from moisture.

Avoid Interactions

Mycophenolate Mofetil interacts with several medicines that can alter its efficacy or safety.

Major Interactions (Avoid)

  • Rifampin or other strong CYP3A4 inducers: markedly reduce mycophenolate exposure.
  • Azathioprine: additive myelosuppression risk.
  • Live vaccines: increased risk of infection.
  • Cholestyramine or bile‑acid sequestrants: decrease oral absorption.

Moderate Interactions (Monitor Closely)

  • Antacids (e.g., aluminum‑magnesium): may lower bioavailability.
  • ACE inhibitors or ARBs: heightened potential for renal dysfunction.
  • NSAIDs: increased risk of nephrotoxicity when combined with mycophenolate.

Frequently Asked Questions

Mycofenolaat Mofetil Accord contains mycophenolate mofetil, an immunosuppressive agent prescribed to prevent rejection of transplanted organs and to treat lupus nephritis, a kidney manifestation of systemic lupus erythematosus.

Mycophenolate mofetil inhibits the enzyme inosine monophosphate dehydrogenase, which is essential for guanosine nucleotide synthesis in lymphocytes. By depleting guanosine pools, it blocks proliferation of T‑ and B‑cells, thereby reducing immune‑mediated damage to transplanted tissue or inflamed kidneys.

The exact dose and dosing schedule are individualized by the prescribing physician based on the patient’s transplant type, renal function, concomitant medications and therapeutic response. No fixed regimen is provided in product literature.

Mycophenolate mofetil is classified as Pregnancy Category D, indicating evidence of fetal risk. It is contraindicated in pregnancy and women of child‑bearing potential should use effective contraception. Limited data exist for breastfeeding, and the drug is generally avoided.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Both drugs are immunosuppressants, but mycophenolate mofetil has a more selective mechanism targeting lymphocyte proliferation, often resulting in a lower incidence of certain toxicities such as hepatotoxicity. Azathioprine is a purine analogue with broader cytotoxic effects and may be preferred in specific clinical scenarios.

Store the tablets at ambient temperature, preferably below 25 °C, in the original container to protect from moisture and light. Do not refrigerate or freeze the product.

The medication is taken orally as a tablet. It may be swallowed with or without food, according to the prescriber’s instructions. Consistency in timing and relation to meals can help maintain stable blood levels.

Serious concerns include opportunistic infections, bone‑marrow suppression leading to low blood counts, hepatic injury, and an increased long‑term risk of certain malignancies. Patients should report signs of infection, unusual bruising, jaundice or persistent fatigue promptly.

The drug is contraindicated in patients with known hypersensitivity to mycophenolate mofetil, in pregnant women, and in individuals with severe uncontrolled infections or severe renal impairment unless dose‑adjusted under specialist supervision.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Mycophenolate Mofetil

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT